Chiusura precedente | 2.774,00 |
Aperto | 2.797,50 |
Denaro | 2.690,00 x 0 |
Lettera | 2.698,00 x 0 |
Min-Max giorno | 2.686,00 - 2.798,00 |
Intervallo di 52 settimane | 1.856,00 - 3.014,50 |
Volume | |
Media Volume | 3.589.325 |
Capitalizzazione | 4,005T |
Beta (5 anni mensile) | 0,50 |
Rapporto PE (ttm) | 37,69 |
EPS (ttm) | 71,57 |
Prossima data utili | 07 ago 2024 - 12 ago 2024 |
Rendimento e dividendo (futuro) | 26,00 (0,94%) |
Data ex dividendo | 27 set 2024 |
Stima target 1A | 3.030,00 |
U.S. Food and Drug Administration (“FDA”) granted Investigational Device Exemption (“IDE”) approval with conditions for Virtue SAB® coronary in-stent restenosis (“ISR”) U.S. pivotal study (in collaboration with Terumo Corporation (“Terumo”)); study expected to start before the end of 2023BackBeat CNT™ global pivotal study in hypertensive pacemaker patients (in collaboration with Medtronic) on track for initiation in the second half of 2023 NEW HOPE, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Orchest
Virtue® Sirolimus AngioInfusion Balloon (“SAB”) is the only non-coated angioplasty system providing protected delivery of extended release sirolimus under clinical investigation worldwideVirtue ISR-US pivotal study focused on coronary in-stent restenosis (“ISR”), a difficult-to-treat and serious complication of coronary stenting, currently expected to start before the end of 2023Strategic partnership with Terumo Corporation (“Terumo”) targets coronary ISR and multiple additional vascular indicat